A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
- Complement 3 Glomerulopathy
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Novartis Pharmaceuticals
- Enrolment target
- 35
- Started
- 22 September 2026
- Main results due
- 15 December 2026
- Study sites
- 1
- Registry updated
- 29 September 2026
Can you take part?
- Ages 18 years to 100 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion criteria: 1. Adult patients (≥18 years). 2. Biopsy-confirmed C3G. 3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025. Exclusion criteria: 1\. Patients treated with iptacopan through an EAP for indications other than C3G.
What this study is about
In the sponsor’s own words, from the registry.
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Study sites(1)
Novartis Investigative Site
Madrid, Spain
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07598448. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me